Effects of peritoneal-and hemodialysis on levels of plasma protein and lipid oxidation markers in diabetic patients

Minerva Medica

Volumn 104, Issue 1, 2013, Pages 75-84

  Sozer, V ^a   Korkmaz Guntas, G ^b   Konukoglu, D ^c   Dervisoglu, E ^d   Gelisgen, R ^c   Tabak, O ^e   Kalender, B ^d   Uzun, H ^c  

^a YILDIZ TECHNICAL UNIVERSITY   (Turkey)

^b School of Health   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d KOCAELI UNIVERSITY   (Turkey)

^e Istanbul Education and Research Hospital   (Turkey)

Author keywords

Diabetes mellitus; Kidney failure, chronic; Oxidative stress; Peritoneal dialysis; Renal dialysis

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; GLUTATHIONE; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMA PROTEIN; PROTEIN CARBOXYL METHYLTRANSFERASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC PATIENT; DIALYSIS; DISEASE EXACERBATION; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HUMAN; LIPID OXIDATION; MALE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; RENAL REPLACEMENT THERAPY; SURVIVAL;

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS; ERYTHROCYTES; FEMALE; GLUTATHIONE; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PROTEIN CARBONYLATION; RENAL DIALYSIS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84876593245     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Amann K, Ritz C, Adamczak M, Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant 2003;18:631-40. (Pubitemid 36432239)
2. Boaz M, Green M, Fainauru M, Smetana S. Oxidative stress and cardiovascular disease in hemodialysis. Clin Nephrol 2001;55:93-100. (Pubitemid 32150995)
3. US Renal Data System. USRDS 1994 annual data report. The National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, July 1994. Am J Kidney Dis 1994;24:S48-S56.
4. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-38. (Pubitemid 35286260)
5. Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 1997;272:20313-6. (Pubitemid 27355575)
6. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003;329:23-38. (Pubitemid 36187411)
7. Giustarini D, Dalle-Donne I, Colombo R, Petralia S, Giampaoletti S, Milzani A et al. Protein glutathionylation in erythrocytes. Clin Chem 2003;49:327-30. (Pubitemid 36157298)
8. Hahn M, Subbiah MT. Significant association of lipid peroxidation products with high density lipoproteins. Biochem Mol Biol Int 1994;33:699-704. (Pubitemid 24229914)
9. Witztum JL, Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
10. Mackness MI, Abbott CA, Arrol S, Durrington PN. The role of high density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem J 1993;294:829-34. (Pubitemid 23286573)
11. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91.
12. Burkart JM, Depner TA. End-stage renal disease and dialysis. NephSAP 2005,4:293-350.
13. Ronco C, Bowry S, Tetta C. Dialysis patients and cardiovascular problems: Can technology help solve the complex equation? Blood Purif 2006;24:39-45. (Pubitemid 41820820)
14. World Medical Association. World Medical Association Declaration Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002;48:206-8.
15. Reznick AZ, Packer L. Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233:357-63.
16. Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978;52:302-10.
17. Hasselwander O, Savage DA, McMaster D, Loughrey CM, McNamee PT, Middleton D et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999;56:289-98. (Pubitemid 29300547)
18. Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol 1994;233:381-5.
19. Beutler E, Duran O, Kelly MB. Improved method for the determination of blood glutathione. J Lab Clin Med 1963;61:882-8.
20. Shinzato T, Nakai S, Fujita Y, Takai I, Morita H, Nakane K et al. Determination of Kt/V and protein catabolic rate using pre- and postdialysis blood urea nitrogen concentrations. Nephron 1994;67:280-90. (Pubitemid 24177635)
21. García-López E, Carrero JJ, Suliman ME, Lindholm B, Stenvinkel P. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int 2007;27(Suppl 2):S205-209. (Pubitemid 350047702)
22. Uzun H, Konukoglu D, Besler M, Erdenen F, Sezgin C, Muderrisoglu C. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide, and C-reactive protein levels. Clin Invest Med 2008;31:E1-7. (Pubitemid 351272174)
23. Fenton SS, Schaubel DE, Desmeules M, Morrison HI, Mao Y, Copleston P et al. Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis 1997;30:334-42. (Pubitemid 27391500)
24. Cheung AK. Biocompatibility of dialysis membranes. J Am Soc Nephrol 1990;1:150-61.
25. Boran M, Kucukaksu C, Balk M, Cetin S. Red cell lipid peroxidation and antioxidant system in haemodialysed patients: influence of recombinant human erythropoietin (r-HuEPO) treatment. Int Urol Nephrol 1998;30:507-12. (Pubitemid 28505795)
26. Ward RA. Phatocytic cell function as an index of biocompatibility. Nephrol Dial Transplant 1994;9:46-56. (Pubitemid 24136237)
27. Caimi G, Carollo C, Montana M, Iatrino R, Bondi B, Lo Presti R. Nitric oxide metabolites, leukocyte activation markers, and oxidative status in dialyzed subjects. Blood Purif 2009;27:194-8.
28. Mayer B, Zitta S, Greilberger J, Holzer H, Reibnegger G, Hermetter A et al. Effect of hemodialysis on the antioxidative properties of serum. Biochimica et Biophysica Acta 2003;1638;267-72. (Pubitemid 37288965)
29. Biasioli S, Schiavon R, Petrosino L, Cavallini L, Zambello A, De Fanti E et al. Free radicals and oxidative stress challenge dialysis patients: Effects of two different membranes. ASAIO J 1997;43:M766-772. (Pubitemid 27473208)
30. Bloembergen WE, Port FK, Elizabeth A, Mauger EA, Wolfe RA. Comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995;6:184-91.
31. Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T et al. Different risk factors for peripheral vascular calcification between diabetic and non-diabetic haemodialysis patients - importance of glycaemic control. Diabetologia 2002;45:1446-8. (Pubitemid 35244899)
32. Krane V, Heinrich F, Meesmann M, Olschewski M, Lilienthal J, Angermann C et al. German Diabetes and Dialysis Study Investigators. Clin J Am Soc Nephrol 2009;4:394-400.
33. Bashan N, Kovsan J, Kachko I, Ovadia H, Rudich A. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 2009;89:27-71.
34. Dursun E, Dursun B, Suleymanlar G, Ozben T. Effect of haemodialysis on the oxidative stress and antioxidants in diabetes mellitus. Acta Diabetol 2005;42:123-8. (Pubitemid 41551999)
35. Beckert S, Sundermann K, Wolf S, Königsrainer A, Coerper S. Haemodialysis is associated with changes in cutaneous microcirculation in diabetes mellitus. Diabet Med 2009;26:89-92.
36. Held PJ, Port FK, Turenne MN, Gaylin DS, Hamburger RJ, Wolfe RA. Continuous ambulatory peritoneal dialysis and hemodialysis: comparison of patient mortality with adjustment for comorbid conditions. Kidney Int 1994;45:1163-9. (Pubitemid 24234735)
37. Passadakis P, Oreopoulos D. Peritoneal dialysis in diabetic patients. Adv Ren Replace Ther. 2001;8:22-41. (Pubitemid 32151802)
38. Daugirdas JT, Depner TA, Gotch FA, Greene T, Keshaviah P, Levin NW et al. Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study. Kidney Int 1997;52:1395-405. (Pubitemid 27496071)
39. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study of the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004;15:1061-70. (Pubitemid 38375326)